Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Solid Biosciences logo — #TogetherWeAreSolid

Solid Biosciences

#TogetherWeAreSolid

Founded 2013 United States Boston, United States 161 employees Post-IPO Equity Total: $610.30M Biotechnology, Health Care

General Information

Company Name Solid Biosciences
Founded Year 2013
Location United States Boston, United States
Employees 161
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Solid Biosciences. To contact Solid Biosciences, visit solidbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Solid Biosciences compare?

A PDF of Solid Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Solid Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 06, 2026

Solid Biosciences announced Solid Biosciences will be attending the 2026 Friedreich's Ataxia Symposium, hosted by FARA and Children’s Hospital of Philadelphia.

Get alerts when Solid Biosciences shows new signals

About Solid Biosciences

Solid Biosciences, founded in 2013 and headquartered in Charlestown, MA, USA, is a trailblazer in the biotechnology sector, especially in precision genetic medicine. Their motto, #TogetherWeAreSolid, reflects their commitment to advancing gene therapy solutions for rare neuromuscular and cardiac diseases.

Solid's innovative portfolio, including candidates like SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich’s ataxia, positions it at the forefront of healthcare technology and impact. The company's dedication to enhancing gene therapy delivery is further emphasized by their focus on developing genetic regulators and enabling technologies.

Solid Biosciences recently attracted significant attention from investors by securing a $109.00M post-IPO equity investment on 08 January 2024. This funding round drew support from renowned investors such as RA Capital Management, Invus, and Bain Capital Life Sciences, underlining industry confidence in Solid's mission and technological pipeline.

Business keywords: Precision Genetic Medicine, Gene Therapy, Rare Neuromuscular Diseases, Cardiac Diseases, Duchenne Muscular Dystrophy, Friedreich’s Ataxia, Catecholaminergic Polymorphic Ventricular Tachycardia, Dilated Cardiomyopathy, Genetic Regulators, Gene Therapy Delivery, Dystrophin Protein Restoration, Orphan Drug Designation, Rare Pediatric Disease Designation, Preclinical Program, Phase I/II Clinical Trial

Services & Products

Gene Therapy Development
Clinical Trials
Research Collaborations
Licensing Opportunities
Manufacturing Infrastructure

Target Customers

Patients with Rare Neuromuscular Diseases Patients with Cardiac Diseases Medical Researchers Healthcare Providers Biotechnology Collaborators

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $109.00M 8
RA Capital Management Invus Adage Capital Management
RA Capital Management, Invus +6
08 Jan 2024
Post IPO Equity $75.00M 7
Pura Vida Investments RA Capital Management Invus
Pura Vida Investments, RA Capital Management +5
30 Sep 2022
Post IPO Equity $143.80M -
19 Mar 2021
Post IPO Equity $90.00M 8
RA Capital Management Boxer Capital EcoR1 Capital
RA Capital Management, Boxer Capital +6
11 Dec 2020
Post IPO Equity $40.00M 1
Ultragenyx Pharmaceutical
23 Oct 2020
Post IPO Equity $60.00M 7
RA Capital Management Boxer Capital Invus
RA Capital Management, Boxer Capital +5
26 Jul 2019
Series C $50.00M 9
RA Capital Management Foresite Capital Perceptive Advisors
RA Capital Management, Foresite Capital +7
30 Mar 2017
Series B $42.50M 1
Perceptive Advisors
Perceptive Advisors
03 Nov 2015
Seed Round Undisclosed 1
JP Morgan
31 Jan 2014

Solid Biosciences Alternatives & Competitors

View All Alternatives
Solid Biosciences vs
Dyne Therapeutics
Dyne Therapeutics United States

Advancing life-transforming therapies for serious muscle diseases

Post-IPO Equity
292 employees
Biotechnology, Health Care
Solid Biosciences vs
Renovacor
Renovacor

Advancing transformative therapies for cardiovascular disease

Post-IPO Equity
6 employees
Biotechnology, Health Care
Solid Biosciences vs
AskBio Inc.
AskBio Inc. United States

Pioneering science to create transformative molecular medicines.

Grant
526 employees
Biopharma, Biotechnology
Also compare with: Solid Biosciences vs Ultragenyx Ultragenyx View all alternatives

FAQ About Solid Biosciences

#TogetherWeAreSolid
Solid Biosciences was founded in 2013.
Solid Biosciences is headquartered in Boston, United States.
Solid Biosciences operates in Biotechnology and Health Care. Its work centres on Precision Genetic Medicine, Gene Therapy, Rare Neuromuscular Diseases and Cardiac Diseases. Its customers include Patients with Rare Neuromuscular Diseases, Patients with Cardiac Diseases and Medical Researchers.
Solid Biosciences has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
Solid Biosciences has approximately 161 employees.
Solid Biosciences has completed 9 funding rounds, raising a total of $610.30M. The latest funding stage is Post-IPO Equity.
Solid Biosciences offers: Gene Therapy Development, Clinical Trials, Research Collaborations, Licensing Opportunities, Manufacturing Infrastructure.
Top alternatives and competitors to Solid Biosciences include Dyne Therapeutics, Renovacor, AskBio Inc., Ultragenyx, Rocket Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Solid Biosciences and Dyne Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Solid Biosciences, https://bouncewatch.com/company/solid-biosciences, updated 2 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes